Across TCGA pan-cancer cohorts, FAM222B mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated FAM222B data layer compared with 27 for mass-spec protein and 3 for mutation status.
The strongest signal is observed in lung adenocarcinoma (LUAD), where higher FAM222B mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated FAM222B expression acts as an unfavorable survival marker.
LUAD are the cancer types where FAM222B mass-spec protein most reproducibly stratifies survival.